Here are the 10-K annual reports from Voyager Acquisition Corp (VACH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VACH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VACH filings page.
Voyager Acquisition Corp. filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The sole purpose of this amendment is to add Exhibit 97.1, the company’s Policy on Recoupment of Incentive Compensation, which was adopted as of March 10, 2025 and was inadvertently omitted previously.
The company states that no other changes have been made, and the original annual report continues to speak as of, and for, the periods it covers. As context, the aggregate market value of outstanding Class A ordinary shares held by non‑affiliates was $263 million as of June 30, 2025, and there were 25,300,000 Class A ordinary shares and 6,325,000 Class B ordinary shares outstanding as of March 10, 2026.
Voyager Acquisition Corp., a Cayman Islands SPAC listed on Nasdaq (units VACHU, shares VACH, warrants VACHW), filed its annual report for the year ended December 31, 2025. The company raised $253,000,000 in its August 12, 2024 IPO, selling 25,300,000 units at $10.00 each into a trust initially funding about $10.05 per public share.
Voyager is targeting healthcare and healthcare-related businesses. On April 22, 2025 it signed a Business Combination Agreement with Veraxa Biotech AG, later joined by Veraxa Biotech Holding AG (PubCo) and Veraxa Cayman Merger Sub. The structure contemplates Voyager merging into Merger Sub and Veraxa merging into PubCo, creating a Swiss-listed parent.
Amendments extended the agreement end date to August 7, 2026, removed a SPAC termination fee in certain terminations, and on February 2, 2026 raised the implied merger consideration to about $1.35 billion while waiving the net tangible asset condition and providing for the sponsor to surrender 200,000 founder shares and 400,000 private placement warrants at closing.
As of December 31, 2025, non-affiliate equity had an aggregate market value of approximately $270 million, and as of March 10, 2026 there were 25,300,000 Class A ordinary shares and 6,325,000 Class B ordinary shares outstanding. The SPAC has 24 months from IPO closing, subject to shareholder-approved extensions, to complete a business combination or redeem public shares and liquidate, with detailed redemption, voting, and creditor-protection mechanics outlined.